Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Compare with peers Embed
What it said it expected, against what it reported

5 targets with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 3 of 5 range targets
Below the range 1 below the last range given

The numbers AMRX said it expected, in its earnings releases, next to what it then reported for the same period. 1 full-year target was dropped quietly: the next release, before the year ended, gave other targets for that year but said nothing about this one.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given $740.00M to $770.00M release Apr 22, 2026
Kept $740.00M to $770.00M release May 7, 2026
Raised $750.00M to $780.00M release Jul 30, 2026
– No standard number
The company's words
2026 Updated Guidance 2026 Prior Guidance … Adjusted EBITDA (1) $740 million - $770 million release Apr 22, 2026
Affirming Previously Announced (on April 22, 2026) Increased 2026 Full Year Guidance … Adjusted EBITDA(1) $740 million - $770 million release May 7, 2026
Updated Guidance Prior Guidance … Adjusted EBITDA(1) $750 million - $780 million release Jul 30, 2026
Operating cash flow
Fiscal 2026
Given $350.00M to $400.00M release Apr 22, 2026
Kept $350.00M to $400.00M release May 7, 2026
Kept $350.00M to $400.00M release Jul 30, 2026
– Not reported yet
The company's words
2026 Updated Guidance 2026 Prior Guidance … Operating cash flow $350 million - $400 release Apr 22, 2026
Affirming Previously Announced (on April 22, 2026) Increased 2026 Full Year Guidance … Operating cash flow(3) $350 million - $400 million release May 7, 2026
Updated Guidance Prior Guidance … Operating cash flow(3) $350 million - $400 million release Jul 30, 2026
Operating cash flow (company-defined)
Fiscal 2026
Given $375.00M to $425.00M release Apr 22, 2026
Kept $375.00M to $425.00M release May 7, 2026
Kept $375.00M to $425.00M release Jul 30, 2026
– No standard number
The company's words
2026 Updated Guidance 2026 Prior Guidance … Operating cash flow, excluding $375 million - $425 million release Apr 22, 2026
Affirming Previously Announced (on April 22, 2026) Increased 2026 Full Year Guidance … Operating cash flow, excluding discrete $375 million - $425 million release May 7, 2026
Updated Guidance Prior Guidance … Operating cash flow, excluding discrete $375 million - $425 million release Jul 30, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $0.95 to $1.05 release Apr 22, 2026
Kept $0.95 to $1.05 release May 7, 2026
Dropped quietly release Jul 30, 2026 ⓘ
– No standard number
The company's words
2026 Updated Guidance 2026 Prior Guidance … Adjusted diluted EPS $0.95 - $1.05 release Apr 22, 2026
Affirming Previously Announced (on April 22, 2026) Increased 2026 Full Year Guidance … Adjusted diluted EPS(2) $0.95 - $1.05 release May 7, 2026
Revenue
Fiscal 2026
Given $625.00M to $700.00M release Feb 27, 2026
Raised $3.05B to $3.15B release Apr 22, 2026
Kept $3.05B to $3.15B release May 7, 2026
Raised $3.10B to $3.20B release Jul 30, 2026
– Not reported yet
The company's words
2026 Full Year Financial Guidance … (1) The Company expects Affordable Medicines net revenue to grow 7% to 8%, Specialty net revenue to be flat year-over-year, and AvKARE to generate $625 million to $700 million net revenue. release Feb 27, 2026
2026 Updated Guidance 2026 Prior Guidance … Net revenue $3.05 billion - $3.15 billion release Apr 22, 2026
Affirming Previously Announced (on April 22, 2026) Increased 2026 Full Year Guidance … Net revenue $3.05 billion - $3.15 billion release May 7, 2026
Updated Guidance Prior Guidance … Net revenue $3.10 billion - $3.20 billion release Jul 30, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $650.00M to $675.00M release May 2, 2025
Raised $665.00M to $685.00M release Aug 5, 2025
Raised $675.00M to $685.00M release Oct 30, 2025
– No standard number
The company's words
The Company is affirming its previously provided full year 2025 guidance. … Adjusted EBITDA(1) $650 million - $675 million release May 2, 2025
Updated Guidance Prior Guidance … Adjusted EBITDA(1) $665 million - $685 million release Aug 5, 2025
Updated Guidance Prior Guidance … Adjusted EBITDA(1) $675 million - $685 million release Oct 30, 2025
Operating cash flow
Fiscal 2025 (ended Dec 31, 2025)
Given $255.00M to $285.00M release May 2, 2025
Raised $275.00M to $305.00M release Aug 5, 2025
Raised $300.00M to $330.00M release Oct 30, 2025
$339.99M
10-K filed 2026-02-27
Above the range
The company's words
The Company is affirming its previously provided full year 2025 guidance. … Operating cash flow $255 million - $285 million release May 2, 2025
Updated Guidance Prior Guidance … Operating cash flow $275 million - $305 million release Aug 5, 2025
Updated Guidance Prior Guidance … Operating cash flow $300 million - $330 million release Oct 30, 2025
Operating cash flow (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $280.00M to $310.00M release May 2, 2025
Raised $300.00M to $330.00M release Aug 5, 2025
Kept $300.00M to $330.00M release Oct 30, 2025
– No standard number
The company's words
The Company is affirming its previously provided full year 2025 guidance. … Operating cash flow, excluding discrete $280 million - $310 million release May 2, 2025
Updated Guidance Prior Guidance … Operating cash flow, excluding discrete $300 million - $330 million release Aug 5, 2025
Updated Guidance Prior Guidance … Operating cash flow, excluding discrete $300 million - $330 million release Oct 30, 2025
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $0.65 to $0.70 release May 2, 2025
– No standard number
The company's words
The Company is affirming its previously provided full year 2025 guidance. … Adjusted diluted EPS(2) $0.65 - $0.70 release May 2, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $3.00B to $3.10B release May 2, 2025
Kept $3.00B to $3.10B release Aug 5, 2025
Kept $3.00B to $3.10B release Oct 30, 2025
$3.02B
10-K filed 2026-02-27
Within the range
The company's words
The Company is affirming its previously provided full year 2025 guidance. … Net revenue $3.0 billion - $3.1 billion release May 2, 2025
Updated Guidance Prior Guidance … Net revenue $3.0 billion - $3.1 billion release Aug 5, 2025
Updated Guidance Prior Guidance … Net revenue $3.0 billion - $3.1 billion release Oct 30, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $580.00M to $620.00M release May 3, 2024
Raised $610.00M to $630.00M release Aug 9, 2024
Kept $610.00M to $630.00M release Nov 8, 2024
– No standard number
The company's words
The Company is affirming its previously provided full year 2024 guidance. … Adjusted EBITDA(1) $580 million - $620 million release May 3, 2024
Updated Guidance Prior Guidance … Adjusted EBITDA(1) $610 million - $630 million release Aug 9, 2024
Affirming Previously Announced Increased 2024 Full Year Guidance … Adjusted EBITDA(1) $610 million - $630 million release Nov 8, 2024
Operating cash flow
Fiscal 2024 (ended Dec 31, 2024)
Given $260.00M to $300.00M release May 3, 2024
Raised $280.00M to $320.00M release Aug 9, 2024
Kept $280.00M to $320.00M release Nov 8, 2024
$295.10M
10-K filed 2025-02-28
Within the range
The company's words
The Company is affirming its previously provided full year 2024 guidance. … Operating cash flow(3) $260 million - $300 million release May 3, 2024
Updated Guidance Prior Guidance … Operating cash flow(3) $280 million - $320 million release Aug 9, 2024
Affirming Previously Announced Increased 2024 Full Year Guidance … Operating cash flow(3) $280 million - $320 million release Nov 8, 2024
Capital expenditures
Fiscal 2024 (ended Dec 31, 2024)
Given $60.00M to $70.00M release May 3, 2024
Kept $60.00M to $70.00M release Aug 9, 2024
Kept $60.00M to $70.00M release Nov 8, 2024
$51.92M
10-K filed 2025-02-28
Below the range
The company's words
The Company is affirming its previously provided full year 2024 guidance. … Capital expenditures $60 million - $70 million release May 3, 2024
Updated Guidance Prior Guidance … Capital expenditures $60 million - $70 million release Aug 9, 2024
Affirming Previously Announced Increased 2024 Full Year Guidance … Capital expenditures $60 million - $70 million release Nov 8, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $0.53 to $0.63 release May 3, 2024
Raised $0.57 to $0.63 release Nov 8, 2024
– No standard number
The company's words
The Company is affirming its previously provided full year 2024 guidance. … Adjusted diluted EPS(2) $0.53 - $0.63 release May 3, 2024
Affirming Previously Announced Increased 2024 Full Year Guidance … Adjusted diluted EPS(2) $0.57 - $0.63 release Nov 8, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $2.55B to $2.65B release May 3, 2024
Raised $2.70B to $2.80B release Aug 9, 2024
Kept $2.70B to $2.80B release Nov 8, 2024
$2.79B
10-K filed 2025-02-28
Within the range
The company's words
The Company is affirming its previously provided full year 2024 guidance. … Net revenue $2.55 billion - $2.65 billion release May 3, 2024
Updated Guidance Prior Guidance … Net revenue $2.70 billion - $2.80 billion release Aug 9, 2024
Affirming Previously Announced Increased 2024 Full Year Guidance … Net revenue $2.70 billion - $2.80 billion release Nov 8, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Capital expenditures, Fiscal 2025 (ended Dec 31, 2025): said $20.00M, reported $70.06M. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-03-01), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.